Development of recombinant vaccine for lassa fever using replication-incompetent rabies viral vector.

拉沙热是一种急性病毒性疾病，目前还没有有效的候选疫苗。据报道，细胞免疫在预防拉沙热中起主要作用。复制能力不强的活病毒疫苗有望成为拉沙热的候选疫苗。为了评价无复制能力的横纹病毒载体用于拉沙热疫苗的免疫原性，我们新构建了不含狂犬病P基因的重组狂犬病病毒Delta-P-GPC株，其基因组中含有淋巴细胞脉络膜脑膜炎病毒(LCMV)GPC基因。免疫荧光法和免疫印迹法证实了GPC蛋白在感染狂犬病P蛋白的BHK细胞中的表达。80%的小鼠经肌肉注射二次免疫。和IP。路线，在我们所分离的LCMV的致命挑战下幸存下来。

Lassa fever is an acute viral illness, and there is no effective vaccine candidate available. It has been reported that cellular immunity plays the major roles in the prevention against lassa fever. Replication-incompetent live viral vaccine would be a promising vaccine candidate for lassa fever. To evaluate the immunogenicity of the replication-incompetent rhabdovirus vector for vaccine against lassa fever, we newly generated the recombinant rabies virus, delta-P-GPC strain, which lacks rabies P gene and possesses lymphocytic choriomeningitis virus (LCMV) GPC gene in its genome. We confirmed the GPC protein expression in delta-P-GPC strain infected rabies P protein expressing BHK cells by immunofluorescence assay and western blot. 80% of mice immunized twice with delta-P-GPC by i.m. and i.p. route, survived against lethal challenge with LCMV WE strain.